SG10201507819VA - Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency - Google Patents
Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid DeficiencyInfo
- Publication number
- SG10201507819VA SG10201507819VA SG10201507819VA SG10201507819VA SG10201507819VA SG 10201507819V A SG10201507819V A SG 10201507819VA SG 10201507819V A SG10201507819V A SG 10201507819VA SG 10201507819V A SG10201507819V A SG 10201507819VA SG 10201507819V A SG10201507819V A SG 10201507819VA
- Authority
- SG
- Singapore
- Prior art keywords
- treating
- methods
- disorders associated
- therapeutic regimen
- visual disorders
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/11—Aldehydes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/222—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having aromatic groups, e.g. dipivefrine, ibopamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
- A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32576310P | 2010-04-19 | 2010-04-19 | |
| US40743610P | 2010-10-27 | 2010-10-27 | |
| US201161447611P | 2011-02-28 | 2011-02-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201507819VA true SG10201507819VA (en) | 2015-10-29 |
Family
ID=44788663
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201507819VA SG10201507819VA (en) | 2010-04-19 | 2011-04-19 | Therapeutic Regimen And Methods For Treating Or Ameliorating Visual Disorders Associated With An Endogenous Retinoid Deficiency |
| SG2012078143A SG184971A1 (en) | 2010-04-19 | 2011-04-19 | Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012078143A SG184971A1 (en) | 2010-04-19 | 2011-04-19 | Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency |
Country Status (18)
| Country | Link |
|---|---|
| US (3) | US9173856B2 (en) |
| EP (1) | EP2563350B1 (en) |
| JP (4) | JP6250389B2 (en) |
| KR (2) | KR20180043846A (en) |
| CN (2) | CN107308143A (en) |
| AU (3) | AU2011244024B2 (en) |
| BR (1) | BR112012026939A2 (en) |
| CA (1) | CA2796991A1 (en) |
| CL (1) | CL2012002942A1 (en) |
| CO (1) | CO6640227A2 (en) |
| HK (1) | HK1246171A1 (en) |
| IL (1) | IL222567A (en) |
| MX (1) | MX339834B (en) |
| NO (1) | NO20121362A1 (en) |
| NZ (1) | NZ603331A (en) |
| RU (1) | RU2622763C2 (en) |
| SG (2) | SG10201507819VA (en) |
| WO (1) | WO2011132084A2 (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5663025B2 (en) | 2009-09-15 | 2015-02-04 | キューエルティー インコーポレイテッド | Pharmaceutical formulation comprising 9-cis-retinyl ester in a lipid vehicle |
| RU2622763C2 (en) | 2010-04-19 | 2017-06-19 | Новелион Терапьютикс Инк. | Regimen and methods of treatment or reduction of visual disturbances, associated with deficient endogenous retinoids |
| WO2013134867A1 (en) * | 2012-03-01 | 2013-09-19 | Qlt Inc. | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
| WO2015023902A2 (en) * | 2013-08-14 | 2015-02-19 | Qlt Inc. | Therapeutic regimens and methods for improving visual function in visual disorders associated with impaired dark adaptation and/or impaired low luminance vision |
Family Cites Families (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3196078A (en) | 1962-01-30 | 1965-07-20 | Ortho Pharma Corp | Process for combating retinits pigmentosa |
| US3517067A (en) | 1964-02-11 | 1970-06-23 | Eastman Kodak Co | Syntheses of quaternary phosphonium salts |
| DE2300107C2 (en) | 1973-01-03 | 1982-03-11 | Basf Ag, 6700 Ludwigshafen | Vitamin A acid anilide-4-carboxylic acid ethyl ester, process for its production and preparations containing it |
| CH590222A5 (en) | 1973-08-21 | 1977-07-29 | Hoffmann La Roche | |
| US4022913A (en) | 1973-09-13 | 1977-05-10 | Hoffmann-La Roche Inc. | High potency vitamin A compositions |
| DE2456959A1 (en) | 1974-12-03 | 1976-06-16 | Basf Ag | 4- (E) - AND 4- (Z) -7-METHYL-9- (2,6,6TRIMETHYL-1-CYCLOHEXEN-1-YL) -NONA-2,4,6,8TETRAEN CARBONIC ACID, ITS DERIVATIVES AND CONTAINING THEM PREPARATIONS |
| US4532133A (en) | 1983-05-24 | 1985-07-30 | Basf Wyandotte Corporation | Low temperature stable, emulsifiable vitamin A concentrates |
| CA1282326C (en) | 1984-12-14 | 1991-04-02 | Paul J. Jarosz | Pharmaceutical composition containing 13-cis vitamin a acid as the active ingredient |
| JPS61275266A (en) | 1985-05-28 | 1986-12-05 | Taisho Pharmaceut Co Ltd | Retinoid derivative |
| CZ282548B6 (en) | 1992-01-22 | 1997-08-13 | F. Hoffmann-La Roche Ag | Application of 9-cis-retinic acid |
| US5310764A (en) | 1992-05-08 | 1994-05-10 | Steven Baranowitz | Treatment of age related macular degeneration with beta-carotene |
| JPH06340525A (en) | 1993-06-02 | 1994-12-13 | Lion Corp | Stable eye lotion containing solubilized vitamin a and having low stimulation to eye |
| WO1995026734A1 (en) | 1994-04-04 | 1995-10-12 | Freeman William R | Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure |
| US5425560A (en) | 1994-04-21 | 1995-06-20 | Strattec Security Corporation | Squeeze latch |
| RU2106843C1 (en) | 1994-06-29 | 1998-03-20 | Красноярская государственная медицинская академия | Method to treat myopia |
| JPH08198746A (en) | 1995-01-18 | 1996-08-06 | Lion Corp | Solubilized eye drop |
| US5837728A (en) | 1995-01-27 | 1998-11-17 | Molecular Design International | 9-cis retinoic acid esters and amides and uses thereof |
| US5489611A (en) | 1995-02-10 | 1996-02-06 | Warner-Lambert Company | Method for lowering plasma levels of lipoprotein (a) |
| US5620970A (en) | 1995-06-05 | 1997-04-15 | Alcon Laboratories, Inc. | Topical ophthalmic carbonic anhydrase inhibitor formulations |
| AU6390096A (en) | 1995-07-20 | 1997-02-18 | Pharmacia & Upjohn Company | Stable clear solutions of non-steroidal anti-inflammatory drugs for incorporation into gelatin capsules |
| US5716627A (en) | 1996-04-25 | 1998-02-10 | Elizabeth Arden Co., Division Of Conopco, Inc. | Skin care compositions containing fatty acid amides, azoles, and retinol or retinyl ester |
| EP0908179A1 (en) | 1997-08-23 | 1999-04-14 | Werner Bollag | Treatment of cell-mediated immune diseases |
| ZA989513B (en) | 1997-10-21 | 1999-04-21 | Alcon Lab Inc | Compositions containing histamine H2 agonists and methods of use in treating dry eye |
| US6391924B1 (en) | 1997-12-10 | 2002-05-21 | Hampar Karageozian | Taurine derivatives useable in the treatment of ophthalmic disorders |
| US6552009B2 (en) | 1998-07-16 | 2003-04-22 | Gentrix Llc | Compositions and methods of treating abnormal cell proliferation |
| US6267985B1 (en) | 1999-06-30 | 2001-07-31 | Lipocine Inc. | Clear oil-containing pharmaceutical compositions |
| US6372463B1 (en) | 1999-05-06 | 2002-04-16 | The President & Fellows Of Harvard College | Mutations in nucleic acid molecules encoding 11-CIS retinol dehydrogenase, the mutated proteins, and uses thereof |
| US6300328B1 (en) | 1999-08-06 | 2001-10-09 | Alcon Universal Ltd. | Selective inhibitors of adenosine monophosphate deaminase for the treatment of optic nerve and retinal damage |
| US20020028849A1 (en) | 2000-04-18 | 2002-03-07 | Godkin James D. | Use of retinol in assisted-reproduction protocols |
| US6696069B2 (en) | 2000-06-30 | 2004-02-24 | Unilever Home & Personal Care Usa, Division Of Conopco, Inc. | Skin care cosmetic compositions containing phosphates and/or sulfates of branched alcohols and/or ethoxylates thereof |
| US20040077604A1 (en) | 2001-12-19 | 2004-04-22 | Lenard Lichtenberger | Method and compositions employing formulations of lecithin oils and nsaids for protecting the gastrointestinal tract and providingenhanced therapeutic activity |
| WO2002055540A1 (en) | 2001-01-11 | 2002-07-18 | Chebigen Inc. | New retinol derivatives, the method of preparations and the uses thereof |
| EP1381276A4 (en) | 2001-04-13 | 2005-02-02 | Univ Pennsylvania | Method of treating or retarding the development of blindness |
| ITMI20012366A1 (en) | 2001-11-09 | 2003-05-09 | Farmatron Ltd | THERAPEUTIC SYSTEMS STABILIZED WITH IMMEDIATE RELEASE AND / OR MODIFIED FOR THE ORAL ADMINISTRATION OF ACTIVE AND / OR EXCIPIENT PRINCIPLES AND / OR WINGS |
| CN1671379A (en) | 2001-11-30 | 2005-09-21 | Qlt公司 | Hydrazonopyrazole derivatives and their use as therapeutics |
| JP2005524626A (en) | 2002-01-18 | 2005-08-18 | タットン テクノロジーズ エルエルシー． | Methods for treating eye diseases |
| US20030215413A1 (en) | 2002-03-22 | 2003-11-20 | L'oreal | Compositions containing stabilized retinoid |
| US20040097587A1 (en) | 2002-03-27 | 2004-05-20 | Arbiser Jack L | Compositions and methods of treatment of ulcerating diseases, burns, and related conditions |
| EP1536819A4 (en) | 2002-03-29 | 2007-10-17 | Maxim Pharm Inc | Use of rom production and release inhibitors to treat and prevent intraocular damage |
| JP3854524B2 (en) | 2002-04-01 | 2006-12-06 | ピアス株式会社 | Oil-soluble component stabilizing composition, cosmetic containing the composition, and method for stabilizing oil-soluble component |
| EP1527774A1 (en) | 2003-11-03 | 2005-05-04 | Basilea Pharmaceutica AG | New formulation for retinoid-containing soft gelatin capsules |
| EP2324823A3 (en) * | 2003-03-14 | 2011-11-16 | University of Washington | Retinoid replacements and opsin agonists and methods for the use thereof |
| EP1510133A1 (en) | 2003-09-01 | 2005-03-02 | Belovo S.A., Egg Science & Technology | Balanced oil composition |
| ES2563733T3 (en) | 2003-09-04 | 2016-03-16 | The Uab Research Foundation | Procedure and apparatus for detecting deterioration in dark adaptation |
| US7706863B2 (en) | 2004-01-21 | 2010-04-27 | University Of Washington | Methods for assessing a physiological state of a mammalian retina |
| WO2005079774A2 (en) | 2004-02-17 | 2005-09-01 | President And Fellows Of Harvard College | Management of ophthalmologic disorders, including macular degeneration |
| JP2007529434A (en) | 2004-03-17 | 2007-10-25 | ラース マイケル ラーセン， | Prevention of retinopathy by inhibiting the visual cycle |
| HUE036596T2 (en) * | 2004-06-18 | 2018-07-30 | Univ Washington | Retinal derivatives and methods for the use thereof for the treatment of visual disorders |
| EP2277516A1 (en) * | 2004-06-23 | 2011-01-26 | ReVision Therapeutics, Inc. | Retinyl derivatives for treating ophtalmic conditions |
| US20060240098A1 (en) | 2004-07-14 | 2006-10-26 | Aphios Corporation | Formulations for hyperforin-enriched hypericum fractions |
| AU2005287343A1 (en) | 2004-08-18 | 2006-03-30 | Sirion Therapeutics, Inc. | Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders |
| WO2006039551A2 (en) | 2004-09-30 | 2006-04-13 | The Regents Of The University Of California | Local administration of retinoids to treat deficiencies in dark adaptation |
| US20060177392A1 (en) | 2005-02-10 | 2006-08-10 | William Walden | Oil-based composition for acne |
| US20070104741A1 (en) | 2005-11-07 | 2007-05-10 | Murty Pharmaceuticals, Inc. | Delivery of tetrahydrocannabinol |
| US8202541B2 (en) | 2006-02-07 | 2012-06-19 | U.S. Nutraceuticals, LLC | Dietary supplement composition for blood lipid health |
| EP2069390A4 (en) | 2006-07-27 | 2009-12-30 | Univ Florida | Opsin stabilizing compounds and methods of use |
| PT2125697T (en) | 2007-01-15 | 2016-10-18 | Yu Chongxi | Positively charged water-soluble prodrugs of retinoids and retinoid-like compounds with very high skin penetration rates |
| PT2187880E (en) | 2007-09-12 | 2014-03-25 | Univ Columbia | Compositions and methods for treating macular degeneration |
| BRPI0908154A2 (en) * | 2008-02-11 | 2015-08-11 | Univ Washington | Methods for the treatment and prevention of age-related retinal dysfunctions |
| JP5663025B2 (en) | 2009-09-15 | 2015-02-04 | キューエルティー インコーポレイテッド | Pharmaceutical formulation comprising 9-cis-retinyl ester in a lipid vehicle |
| RU2622763C2 (en) | 2010-04-19 | 2017-06-19 | Новелион Терапьютикс Инк. | Regimen and methods of treatment or reduction of visual disturbances, associated with deficient endogenous retinoids |
| WO2013134867A1 (en) | 2012-03-01 | 2013-09-19 | Qlt Inc. | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency |
-
2011
- 2011-04-19 RU RU2012148812A patent/RU2622763C2/en active
- 2011-04-19 CN CN201710417111.6A patent/CN107308143A/en active Pending
- 2011-04-19 CN CN2011800302646A patent/CN102939081A/en active Pending
- 2011-04-19 US US13/090,215 patent/US9173856B2/en active Active
- 2011-04-19 KR KR1020187010745A patent/KR20180043846A/en not_active Application Discontinuation
- 2011-04-19 MX MX2012012199A patent/MX339834B/en active IP Right Grant
- 2011-04-19 SG SG10201507819VA patent/SG10201507819VA/en unknown
- 2011-04-19 SG SG2012078143A patent/SG184971A1/en unknown
- 2011-04-19 AU AU2011244024A patent/AU2011244024B2/en not_active Ceased
- 2011-04-19 CA CA2796991A patent/CA2796991A1/en not_active Abandoned
- 2011-04-19 NZ NZ603331A patent/NZ603331A/en not_active IP Right Cessation
- 2011-04-19 EP EP11771664.7A patent/EP2563350B1/en active Active
- 2011-04-19 KR KR1020127030132A patent/KR101851249B1/en active IP Right Grant
- 2011-04-19 WO PCT/IB2011/001294 patent/WO2011132084A2/en active Application Filing
- 2011-04-19 JP JP2013505568A patent/JP6250389B2/en active Active
- 2011-04-19 BR BR112012026939A patent/BR112012026939A2/en not_active Application Discontinuation
-
2012
- 2012-10-19 CL CL2012002942A patent/CL2012002942A1/en unknown
- 2012-10-21 IL IL222567A patent/IL222567A/en active IP Right Grant
- 2012-11-19 CO CO12208550A patent/CO6640227A2/en not_active Application Discontinuation
- 2012-11-19 NO NO20121362A patent/NO20121362A1/en not_active Application Discontinuation
-
2013
- 2013-06-25 HK HK18105673.3A patent/HK1246171A1/en unknown
-
2015
- 2015-09-24 JP JP2015187459A patent/JP2016014047A/en active Pending
- 2015-10-05 US US14/875,342 patent/US9987245B2/en active Active
-
2016
- 2016-03-04 AU AU2016201432A patent/AU2016201432A1/en not_active Abandoned
-
2017
- 2017-09-29 JP JP2017189573A patent/JP2017222721A/en active Pending
- 2017-12-03 AU AU2017268684A patent/AU2017268684A1/en not_active Abandoned
-
2018
- 2018-05-01 US US15/968,358 patent/US20190029986A1/en not_active Abandoned
-
2019
- 2019-06-27 JP JP2019120244A patent/JP2019178162A/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HK1204271A1 (en) | Methods of reducing the risk of a cardiovascular event in a subject on statin therapy | |
| EP2670733A4 (en) | Hdac inhibitors and therapeutic methods using the same | |
| IL227678B (en) | Triterpenoids modified in positions 3 and 17 | |
| GB2492597B (en) | Transformer with an inverter system and an inverter system comprising the transformer | |
| EP2731445A4 (en) | Yogurt smoothie kit and methods for making the same | |
| EP2736474A4 (en) | Neuromuscular therapy device and method | |
| EP2680800A4 (en) | Devices and methods for skin tightening | |
| GB201405068D0 (en) | Patient-specific sacroiliac guides and associated methods | |
| IL223889B (en) | Adverse side-effects associated with administration of an anti-hyaluronan agent and methods for ameliorating or preventing the side-effects | |
| IL225246A0 (en) | Methods for accelerated return of skin integrity and for the treatment of impetigo | |
| EP2811915A4 (en) | Bone anchor and related instrumentation and methods | |
| HK1173533A1 (en) | Generating and presenting lateral concepts | |
| ZA201304334B (en) | Methods for diagnosing and treating eye-length related disorders | |
| HK1205469A1 (en) | Therapeutic regimens and methods for improving visual function in visual disorders associated with an endogenous retinoid deficiency | |
| HRP20181950T1 (en) | Samidorphan (alks 33) in combination with buprenorphine for the treatment of depressive disorders | |
| ZA201307770B (en) | Compositions and methods useful for ameliorating age related maladies | |
| PL2917231T3 (en) | Lipopeptides for use in treating liver diseases and cardiovascular diseases | |
| WO2012021287A9 (en) | Methods for the treatment and prevention of metabolic disorders | |
| EP2688585A4 (en) | Methods and compositions for improving antiangiogenic therapy with anti-integrins | |
| HK1246171A1 (en) | Therapeutic regimen and method for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency | |
| EP2640397A4 (en) | Methods for the treatment of fibromyalgia and chronic fatigue syndrome | |
| PL3040329T3 (en) | Aromatic compound and use thereof in the treatment of disorders associated with bone metabolism | |
| PT2670769T (en) | R2r1/2 in diagnosis and therapy | |
| EP2643470A4 (en) | Compositions and methods for diagnosing and treating diseases and disorders associated with d-dt | |
| PT3027213T (en) | Compositions for ameliorating and/or preventing adverse side effects in antibiotic therapy |